Mirtazapine reduces methamphetamine use in Phase 3 trial

A 12‐week Phase 3 study has found that adults with moderate to severe methamphetamine use disorder who received the antidepressant mirtazapine reported a greater decrease in methamphetamine‐using days than those receiving placebo. Use of mirtazapine was not associated with any unexpected safety concerns.

Publication Details

Journal
The Brown University Psychopharmacology Update
Published
2026-06-28
DOI
https://doi.org/10.1002/pu.31475
Primary Topic
Neurotransmitter Receptor Influence on Behavior
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mirtazapine reduces methamphetamine use in Phase 3 trial

The Brown University Psychopharmacology Update
Neurotransmitter Receptor Influence on Behavior
article

Mirtazapine reduces methamphetamine use in Phase 3 trial

article en

Abstract

A 12‐week Phase 3 study has found that adults with moderate to severe methamphetamine use disorder who received the antidepressant mirtazapine reported a greater decrease in methamphetamine‐using days than those receiving placebo. Use of mirtazapine was not associated with any unexpected safety concerns.

The Brown University Psychopharmacology UpdateVol. 37(8)
Good health and well-being
Openalex Percentile: Top 10%
Neurotransmitter Receptor Influence on Behavior
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.